Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa
about
Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individualsCombination implementation for HIV prevention: moving from clinical trial evidence to population-level effectsAntiretroviral drugs-based HIV prevention methods: what impact on the HIV epidemic?Structural approaches for prevention of sexually transmitted HIV in general populations: definitions and an operational approachThe potential impact of pre-exposure prophylaxis for HIV prevention among men who have sex with men and transwomen in Lima, Peru: a mathematical modelling studyThe cost and impact of scaling up pre-exposure prophylaxis for HIV prevention: a systematic review of cost-effectiveness modelling studiesCost-effectiveness of pre-exposure prophylaxis (PrEP) in preventing HIV-1 infections in rural Zambia: a modeling studyAnalytic review of modeling studies of ARV Based PrEP interventions reveals strong influence of drug-resistance assumptions on the population-level effectivenessEffectiveness and cost effectiveness of oral pre-exposure prophylaxis in a portfolio of prevention programs for injection drug users in mixed HIV epidemicsHow Much Do We Know about Drug Resistance Due to PrEP Use? Analysis of Experts' Opinion and Its Influence on the Projected Public Health ImpactOperations research in global health: a scoping review with a focus on the themes of health equity and impactWhere to deploy pre-exposure prophylaxis (PrEP) in sub-Saharan Africa?HIV prevention transformed: the new prevention research agendaCultural conundrums: the ethics of epidemiology and the problems of population in implementing pre-exposure prophylaxis.Estimating HIV incidence among adults in Kenya and Uganda: a systematic comparison of multiple methods.Optimal uses of antiretrovirals for prevention in HIV-1 serodiscordant heterosexual couples in South Africa: a modelling study.ARV-based HIV prevention for women - where we are in 2014.How can we get close to zero? The potential contribution of biomedical prevention and the investment framework towards an effective response to HIV.Pre-exposure prophylaxis of HIV: A right way to go or a long way to go?Targeting pre-exposure prophylaxis among men who have sex with men in the United States and Peru: partnership types, contact rates, and sexual role.Modeling dynamic interactions between pre-exposure prophylaxis interventions & treatment programs: predicting HIV transmission & resistancePre-exposure prophylaxis in Southern Africa: feasible or not?Translating PrEP effectiveness into public health impact: key considerations for decision-makers on cost-effectiveness, price, regulatory issues, distributive justice and advocacy for access.Potential impact of multiple interventions on HIV incidence in a hyperendemic region in Western Kenya: a modelling study.Modelling the impact and cost-effectiveness of combination prevention amongst HIV serodiscordant couples in Nigeria.Fitting HIV Prevalence 1981 Onwards for Three Indian States Using the Goals Model and the Estimation and Projection Package.Mathematical insights in evaluating state dependent effectiveness of HIV prevention interventions.Length of secondary schooling and risk of HIV infection in Botswana: evidence from a natural experiment.Antiviral agents and HIV prevention: controversies, conflicts, and consensus.Preexposure prophylaxis for adolescents and young adults at risk for HIV infection: is an ounce of prevention worth a pound of cure?HIV-1 treatment as prevention: the good, the bad, and the challenges.Advances in the prevention of heterosexual transmission of HIV/AIDS among women in the United States.Evolving uses of oral reverse transcriptase inhibitors in the HIV-1 epidemic: from treatment to preventionEngaging healthcare providers to implement HIV pre-exposure prophylaxis.Bibliometric trends of health economic evaluation in Sub-Saharan Africa.Cost-Effectiveness of Pre-exposure HIV Prophylaxis During Pregnancy and Breastfeeding in Sub-Saharan Africa.Intimate Partner Violence and Adherence to HIV Pre-exposure Prophylaxis (PrEP) in African Women in HIV Serodiscordant Relationships: A Prospective Cohort Study.Impact of Pill Sharing on Drug Resistance Due to a Wide-Scale Oral Prep Intervention in Generalized Epidemics.HIV pre-exposure prophylaxis for people who inject drugs: a review of current results and an agenda for future research.Controlling the HIV epidemic with antiretrovirals: IAPAC consensus statement on treatment as prevention and preexposure prophylaxis.
P2860
Q24201955-69690E29-CD50-4C53-936F-C6477DB0B79FQ24610019-B972D5B4-365E-4051-9A2C-7D473A570361Q26825761-7E735261-5755-45C8-8E79-0F67245997AAQ27008538-92A4A509-585E-4399-B8B8-75C27710DFE3Q28484308-C8EAB6EC-C018-4D81-B689-E21006276F3DQ28487926-33ABE560-8D6E-4E50-9A1D-6CF967D51FFAQ28488157-B69205F1-6E06-4595-8839-33B1A7C2A6EEQ28535414-1B9CCD5B-4313-4C0C-A3F9-998FC6F31E5AQ28539234-92257AC4-869F-4B97-A7E1-0504183786DDQ28552455-D180972C-41F1-4605-89D2-BE0B4A5F4102Q29994616-E0427E46-E9E0-492D-A98A-489BAC6C8106Q30352591-19839057-3AE8-407A-8E0A-F7377D8F1DCBQ30404963-CACBF8EE-92A2-43F9-BC7E-85E8E8E01E21Q33794164-222DF288-9D85-4A4D-BFA6-5B5C2B8A2105Q33847669-B649ACD9-EB41-49CA-BDC6-AFBD4A4DA2C7Q34081339-3265B393-D14A-49E9-B28C-5483B8C73A82Q34180729-DF6B004F-C868-4735-82A4-36E240FC0405Q34457045-347ACF6D-56F9-4808-A46F-BEA98ECA2F23Q35033732-07967D39-A40B-4246-B476-460EA2CDA34DQ35575958-2CEF98A8-2AB0-4BAE-A4F0-8361DF544F1FQ35619584-0102E87C-11BD-4020-8751-F760E1451F27Q35875719-B453CB82-999F-4607-A6FD-DCD942A8FC6BQ35875746-D16BBB09-BCC1-4A3D-A3D9-5ED33614C5A1Q36003735-0AD5B48E-7E9F-47EA-BC90-FFFDF3B1C7DBQ36057387-46183B9E-8365-4DA7-AF2B-E0197D7D3185Q36155310-A2C571EE-F153-4931-8CF9-3B7C9DA89B88Q36274199-9B9E35B5-F3FE-40D8-A6A6-012F090A20D3Q36365683-800CF77A-1445-4231-A3BC-805467B95F38Q36836680-0315AE69-0094-4475-9A83-151CA5B2A7A2Q36853885-6B4DD825-4C08-4580-9816-7FB074DB781DQ36883784-644CFDC1-CB3C-4B6D-AFC2-837796741C88Q36899773-CC45767B-1B23-44A4-BE3D-5A607B0E4A36Q37071435-605FC7DF-951F-40BF-8478-48C38FECE65AQ37161853-732C0AF7-1998-4C04-B5F5-B7C370CF15C1Q37203538-C51B640C-4788-4FA1-B61B-EF22AE2D2818Q37298218-E3A717A3-61B6-427C-9AA0-EC5A7F5B52D7Q37341579-836CA3EE-9912-4FCD-AFA7-EE2BBF10A5B1Q37409926-4D27FC26-3CD0-4BD6-B550-B2D96B70728FQ37671864-0A24E186-7FDC-45FA-BA5A-1B768F499977Q38105957-E3E6BA97-77EE-4070-8616-B0B0F68DD1E4
P2860
Evaluating the cost-effectiveness of pre-exposure prophylaxis (PrEP) and its impact on HIV-1 transmission in South Africa
description
2010 nî lūn-bûn
@nan
2010 թուականի Նոյեմբերին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի նոյեմբերին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Evaluating the cost-effectiven ...... 1 transmission in South Africa
@ast
Evaluating the cost-effectiven ...... 1 transmission in South Africa
@en
type
label
Evaluating the cost-effectiven ...... 1 transmission in South Africa
@ast
Evaluating the cost-effectiven ...... 1 transmission in South Africa
@en
prefLabel
Evaluating the cost-effectiven ...... 1 transmission in South Africa
@ast
Evaluating the cost-effectiven ...... 1 transmission in South Africa
@en
P2093
P2860
P1433
P1476
Evaluating the cost-effectiven ...... 1 transmission in South Africa
@en
P2093
Carel Pretorius
John Stover
Lori Bollinger
P2860
P304
P356
10.1371/JOURNAL.PONE.0013646
P407
P577
2010-11-05T00:00:00Z